Athersys, Inc. is a biopharmaceutical company applying its proprietary stem cell platform MultiStem® to develop products in the areas of regenerative medicine, cardiovascular, neurological, inflammatory and immune diseases.

MultiStem® is currently being evaluated in several preclinical and clinical stage programs.

Athersys, Inc. shares are publicly traded on NASDAQ (NASDAQ:ATHX).